ctDNA responds to neoadjuvant treatment in locally advanced rectal cancer
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05944-7 ↗At a glance
Journal article in Journal of Cancer Research and Clinical Oncology, 2024. Written by Florian Bürtin and 6 co-authors. Institution: Department of General Surgery, Rostock University Medical Center, Rostock, Germany. Major MEDLINE topics: Rectal Neoplasms, Neoadjuvant Therapy, Circulating Tumor DNA. Cited 1 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY 4.0). Funded by: Universitätsmedizin Rostock.
Abstract (original language)
Background
Liquid biopsy is a minimally invasive procedure investigating tumor mutations.
Methods
In our retrospective study, we investigated whether molecular therapy monitoring of patients receiving neoadjuvant radio(chemo)therapy on a daily routine is possible in 17 patients with locally advanced rectal cancer. Six patients received short-course radiotherapy (5 × 5 Gy) with subsequent surgery, six patients were treated according RAPIDO protocol with short-course radiotherapy followed by chemotherapy (FOLFOX4) and subsequent surgery and five patients received conventional neoadjuvant radiochemotherapy with 5-FU followed by surgery. Response was assessed by Dworak. Liquid biopsies were taken before and immediately after neoadjuvant radiotherapy to isolate and ultradeeply sequence cell free DNA with a panel of 127 genes. Somatic mutations were determined bioinformatically by comparison with normal DNA from leukocytes to distinguish them from germline variants or aging mutations.
Results
In 12 patients (71%) at least one somatic mutation was detected. In 8/12 patients a decrease and in 4/12 an increase or mixed response in ctDNA was seen. Statistical correlation between ctDNA analysis and clinical response could not be seen. Conclusion ctDNA is responding to neoadjuvant therapy and liquid biopsy is easily integrated into a daily routine. As part of translational research this protocol leaves room for further investigations.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of General Surgery, Rostock University Medical Center, Rostock, Germany.
- Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Medical Center Schleswig- Holstein, Kiel, Germany.
- Department of Radiotherapy and Radiation Oncology, Rostock University Medical Center, Südring 75, 18059, Rostock, Germany.
- Department of Radiotherapy and Radiation Oncology, Rostock University Medical Center, Südring 75, 18059, Rostock, Germany. felix.bock@med.uni-rostock.de.
Funding
- Universitätsmedizin Rostock
Cite
APA
Bürtin, F., Elias, L., Hinz, S., Forster, M., Hildebrandt, G., Frerker, B., & Bock, F. (2024). ctDNA responds to neoadjuvant treatment in locally advanced rectal cancer. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05944-7
Vancouver
Bürtin F, Elias L, Hinz S, Forster M, Hildebrandt G, Frerker B, et al. ctDNA responds to neoadjuvant treatment in locally advanced rectal cancer. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05944-7
BibTeX
@article{Brtin2024,
author = {Bürtin, Florian and Elias, Liema and Hinz, Sebastian and Forster, Michael and Hildebrandt, Guido and Frerker, Bernd and Bock, Felix},
title = {ctDNA responds to neoadjuvant treatment in locally advanced rectal cancer},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05944-7}
}
EUVIMED